Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Berodual®

Study type: Observational

Funder types: Industry

Identifiers

NCT02232594

215.1358

Details and patient eligibility

About

The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

Enrollment: 834 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease
• Only patients which have not been treated with Berodual® within the last year should be included

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual® metered-dose inhaler

Trial design

834 participants in 1 patient group

chronic obstructive respiratory tract disease patients

Treatment:

Drug: Berodual®